Physician profile
Eva Imperial
NPI 1023018082
$1,151.92
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $69.32 · 2021: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.27 | 2019-2021 | |
| Astellas Pharma US INC | $196.89 | 2019 | |
| Amgen INC. | $158.28 | 2019 | |
| Neos Therapeutics, LP | $29.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $28.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.93 | 2020 | |
| Ibsa Pharma INC. | $16.19 | 2019 | |
| Lilly USA, LLC | $14.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.28 | 2019 | |
| Exeltis, USA INC. | $12.24 | 2019 | |
| Shire North American Group INC | $11.65 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Imperial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.